首页> 美国卫生研究院文献>Radiation Oncology (London England) >Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation
【2h】

Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation

机译:立体定向碘125近距离放射治疗脑肿瘤:临时植入与永久植入

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Stereotactic brachytherapy (SBT) has been described in several publications as an effective, minimal invasive and safe highly focal treatment option in selected patients with well circumscribed brain tumors <4 cm. However, a still ongoing discussion about indications and technique is hindering the definition of a clear legitimation of SBT in modern brain tumor treatment. These controversies encompass the question of how intense the irradiation should be delivered into the target volume (dose rate). For instance, reports about the use of high does rate (HDR) implantation schemes ( >40 cGy/h) in combination with adjuvant external beam radiation and/or chemotherapy for the treatment of malignant gliomas and metastases resulted in increased rates of radiation induced adverse tissue changes requiring surgical intervention. Vice versa, such effects have been only minimally observed in numerous studies applying low dose rate (LDR) regiments (3–8 cGy/h) for low grade gliomas, metastases and other rare indications. Besides these observations, there are, however, no data available directly comparing the long term incidences of tissue changes after HDR and LDR and there is, furthermore, no evidence regarding a difference between temporary or permanent LDR implantation schemes. Thus, recommendations for effective and safe implantation schemes have to be investigated and compared in future studies.
机译:立体定向近距离放射疗法(SBT)在某些出版物中被描述为一种有效的,微创和安全的高度局限性治疗选择,适用于某些局限性脑肿瘤<4 cm的患者。然而,关于适应症和技术的持续讨论阻碍了现代脑肿瘤治疗中SBT合法性的明确定义。这些争议涉及到应将辐照强度传递到目标体积(剂量率)的问题。例如,有关使用高剂量率(HDR)植入方案(> 40 cGy / h)结合辅助外束放射和/或化学疗法治疗恶性神经胶质瘤和转移的报道导致放射诱发的不良不良反应发生率增加组织改变需要手术干预。反之亦然,在许多针对低度神经胶质瘤,转移瘤和其他罕见适应症的应用低剂量率(LDR)方案(3–8 cGy / h)的研究中,仅对这种作用进行了最少的观察。但是,除了这些观察结果之外,没有直接比较HDR和LDR后组织变化的长期发生率的可用数据,此外,也没有关于临时或永久LDR植入方案之间差异的证据。因此,必须对有效和安全的植入方案的建议进行研究,并在以后的研究中进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号